Our Clinical Trials

Here you can find a continually updated listing of Memorial Sloan-Kettering's current clinical trials for soft tissue sarcomas. To learn more about a study, choose from the list below.

Clicking a link below will scroll the
page down to the relevant section

Ewing's Sarcoma
Leiomyosarcoma
Rhabdomyosarcoma
Sarcoma
Soft Tissue Sarcoma

Ewing's Sarcoma

A Phase II Study of Pemetrexed in Children with Recurrent Malignancies
Trippett, Tanya, MD

[Protocol 07-179]
A Phase II Trial of Intravenous Myeloablative Chemotherapy Followed by an Allogeneic Hematopoietic Stem Cell Transplant from a Matched Relative to Treat High-Risk Ewing's Sarcoma Family Tumors
Prockop, Susan, MD

[Protocol 05-059]
A Phase II Trial of R1507 for People with Recurrent Sarcoma
Maki, Robert, MD

[Protocol 07-166]

A Phase II Evaluation of Trabectedin in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Hensley, Martee, MD

[Protocol 07-134]
A Phase II Study Assessing Adjuvant Treatment of High-Risk Uterine Leiomyosarcoma with Gemcitabine/Docetaxel, Followed by Doxorubicin
Hensley, Martee, MD

[Protocol 05-128]

Rhabdomyosarcoma

A Phase II Study of Pemetrexed in Children with Recurrent Malignancies
Trippett, Tanya, MD

[Protocol 07-179]
A Phase II Trial of Irinotecan plus Carboplatin, and Irinotecan Maintenance Therapy Integrated into the Upfront Therapy of Newly Diagnosed Patients with Intermediate- and High-Risk Rhabdomyosarcoma
Wexler, Leonard, MD

[Protocol 03-099]
A Phase II Trial of R1507 for People with Recurrent Sarcoma
Maki, Robert, MD

[Protocol 07-166]
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide in Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid Rhabdomyosarcoma
Wexler, Leonard, MD

[Protocol 05-032]

A Pharmacodynamic Assessment of the Effect of BIIB021 (CNF2024 or CF1983) in Patients with Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not Candidates for Imatinib and Sunitinib
Schwartz, Gary, MD

[Protocol 07-173]
A Phase I Trial of Doxorubicin and Flavopiridol in the Treatment of Metastatic Sarcoma
D'Adamo, David, MD

[Protocol 04-075]
A Phase IB Study Evaluating the Safety of BSI-201 in Combination with Chemotherapeutic Regimens in Patients with Advanced Solid Tumors
Bell-McGuinn, Katherine, MD, PhD

[Protocol 08-048]
A Phase II Evaluation of Trabectedin in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Hensley, Martee, MD

[Protocol 07-134]
A Phase II Study of LY573636 as Second-line or Third-line Treatment in Patients with Unresectable or Metastatic Soft-Tissue Sarcoma
Keohan, Mary, MD

[Protocol 07-177]
A Phase II Study of Pemetrexed in Children with Recurrent Malignancies
Trippett, Tanya, MD

[Protocol 07-179]
A Phase II Study of Sorafenib (BAY 43-9006) for Patients with Imatinib-Resistant Malignant Gastrointestinal Stromal Tumor (GIST)
D'Adamo, David, MD

[Protocol 06-028]
A Phase II Trial of Intravenous Myeloablative Chemotherapy Followed by an Allogeneic Hematopoietic Stem Cell Transplant from a Matched Relative to Treat High-Risk Ewing's Sarcoma Family Tumors
Prockop, Susan, MD

[Protocol 05-059]
A Phase II Trial of Irinotecan plus Carboplatin, and Irinotecan Maintenance Therapy Integrated into the Upfront Therapy of Newly Diagnosed Patients with Intermediate- and High-Risk Rhabdomyosarcoma
Wexler, Leonard, MD

[Protocol 03-099]
A Phase II Trial of Perifosine in Patients with Chemo-Insensitive Sarcomas
Maki, Robert, MD

[Protocol 07-104]
A Phase II Trial of R1507 for People with Recurrent Sarcoma
Maki, Robert, MD

[Protocol 07-166]
Effect of Imatinib on Bone Metabolism, Lipid Metabolism, and Thyroid Function in Patients with Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors
Berman, Ellin, MD

[Protocol 06-142]
Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Cancer and Bone Marrow Transplantation Patients
Meyers, Paul, MD

[Protocol 03-123]
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide in Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid Rhabdomyosarcoma
Wexler, Leonard, MD

[Protocol 05-032]

Soft Tissue Sarcoma

A Phase I Trial of Doxorubicin and Flavopiridol in the Treatment of Metastatic Sarcoma
D'Adamo, David, MD

[Protocol 04-075]
A Phase II Study of LY573636 as Second-line or Third-line Treatment in Patients with Unresectable or Metastatic Soft-Tissue Sarcoma
Keohan, Mary, MD

[Protocol 07-177]
A Phase II Study of Sorafenib (BAY 43-9006) for Patients with Imatinib-Resistant Malignant Gastrointestinal Stromal Tumor (GIST)
D'Adamo, David, MD

[Protocol 06-028]
A Phase II Trial of Intravenous Myeloablative Chemotherapy Followed by an Allogeneic Hematopoietic Stem Cell Transplant from a Matched Relative to Treat High-Risk Ewing's Sarcoma Family Tumors
Prockop, Susan, MD

[Protocol 05-059]
A Phase II Trial of Irinotecan plus Carboplatin, and Irinotecan Maintenance Therapy Integrated into the Upfront Therapy of Newly Diagnosed Patients with Intermediate- and High-Risk Rhabdomyosarcoma
Wexler, Leonard, MD

[Protocol 03-099]
A Phase II Trial of R1507 for People with Recurrent Sarcoma
Maki, Robert, MD

[Protocol 07-166]
Effect of Imatinib on Bone Metabolism, Lipid Metabolism, and Thyroid Function in Patients with Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors
Berman, Ellin, MD

[Protocol 06-142]
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide in Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid Rhabdomyosarcoma
Wexler, Leonard, MD

[Protocol 05-032]

©2008 Memorial Sloan-Kettering Cancer Center.